Barclays PLC lifted its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 466.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 272,029 shares of the biopharmaceutical company’s stock after purchasing an additional 223,995 shares during the quarter. Barclays PLC’s holdings in Arbutus Biopharma were worth $1,047,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of ABUS. Helen Stephens Group LLC bought a new position in shares of Arbutus Biopharma during the third quarter worth about $50,000. XTX Topco Ltd bought a new position in shares of Arbutus Biopharma during the 2nd quarter worth approximately $53,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Arbutus Biopharma by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 14,138 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Arbutus Biopharma in the third quarter worth $142,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Arbutus Biopharma by 453.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,503 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 30,723 shares during the last quarter. 43.79% of the stock is owned by institutional investors.
Arbutus Biopharma Stock Performance
Shares of NASDAQ:ABUS opened at $3.18 on Wednesday. The company has a 50-day simple moving average of $3.45 and a 200 day simple moving average of $3.72. The company has a market capitalization of $602.58 million, a P/E ratio of -7.40 and a beta of 1.78. Arbutus Biopharma Co. has a 52-week low of $2.21 and a 52-week high of $4.72.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Arbutus Biopharma
Arbutus Biopharma Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Recommended Stories
- Five stocks we like better than Arbutus Biopharma
- How to Capture the Benefits of Dividend Increases
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- What is the MACD Indicator and How to Use it in Your Trading
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding ABUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.